Does Acute Treatment with Sedatives/Hypnotics for Anxiety in Depressed Patients Affect Suicide Risk? A Literature Review

References

• Isacsson G, Rich CL. Antidepressant drug use and suicide prevention. Int Rev Psychiatry. 2005;17:153–162.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision. Washington, DC: APA, 2000.
   Google Scholar
• Fawcett J, Scheftner WA, Fogg L, Clark DC, Young MA, Hede-ker D, Gibbons R. Time-related predictors of suicide in major affective disorder. Am J Psychiatry. 1990;147:1189–1194.
   Google Scholar
• Valenstein M, Taylor KK, Austin K, Kales HC, McCarthy JF, Blow FC. Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry. 2004;161:654–661.
   Google Scholar
• Brunton, LL. Goodman & Gilman–s?The Pharmacological Basis of Therapeutics, 11th ed. New York: McGraw-Hill, 2006.
   Google Scholar
• Craig TJ, Van Natta PA. Current medication use and symptoms of depression in a general population. Am J Psychiatry. 1978;135:1036–1039.
   Google Scholar
• James IP. Blood alcohol levels following successful suicide. QJ Stud Alcohol. 1966;27:23–29.
   Google Scholar
• Riddick L, Luke JL. Alcohol-associated deaths in the District of Columbia?A postmortem study. J Forensic Sci. 1978;23:493–502.
   Google Scholar
• Norton LE, Garriott JC, DiMaio VJ. Drug detection at autopsy: A prospective study of 247 cases. J Forensic Sci. 1982;27: 66–71.
   Google Scholar
• Abel EL, Zeidenberg P. Age, alcohol and violent death: A postmortem study. J Stud Alcohol. 1985;46:228–231.
   Google Scholar
• Berkelman RL, Herndon JL, Callaway JL, Stivers R, Howard LB, Bezjak A, Sikes RK. Fatal injuries and alcohol. Am J Prev Med. 1985;1:21–28.
   Google Scholar
• Welte JW, Abel EL, Wieczorek W. The role of alcohol in suicides in Erie County, NY, 1972–84. Public Health Rep. 1988;103: 648–652.
   Google Scholar
• Goodman RA, Istre GR, Jordan FB, Herndon JL, Kelaghan J. Alcohol and fatal injuries in Oklahoma. J Stud Alcohol. 1991;52:156–161.
   Google Scholar
• Kubo S, Dankwarth G, Puschel K. Blood alcohol concentrations of sudden unexpected deaths and non natural deaths. Forensic Sci Int. 1991;52:77–84.
   Google Scholar
• Hayward L, Zubrick SR, Silburn S. Blood alcohol levels in suicide cases. J Epidemiol Community Health. 1992;46:256–260.
   Google Scholar
• Mendelson WB, Rich CL. Sedatives and suicide: The San Diego study. Acta Psychiatr Scand 1993;88:337–341.
   Google Scholar
• Ohberg A, Vuori E, Ojanpera I, Lonngvist J. Alcohol and drugs in suicides. Br J Psychiatry 1996;169:75–80.
   Google Scholar
• Dhossche DM, Rich CL, Isacsson G. Psychoactive substances in suicides. Comparison of toxicologic findings in two samples. Am J Forensic Med Pathol. 2001;22:239–243.
   Google Scholar
• Shields LBE, Hunsaker DM, Hunsaker JC, Ward MK. Toxico-logic findings in suicide. A 10-year retrospective review of Kentucky medical examiner cases. Am J Forensic Med Pathol. 2006;27: 106–112.
   Google Scholar
• Isacsson G, Rich CL. Depression, antidepressants, and suicide: Pharmacoepidemiological evidence for suicide prevention. In: Maris RW, Silverman MM, Canetto SS, eds. Review of Suicidol-ogy. New York: Guilford Publications, 1997:168–201.
   Google Scholar
• Johnstone EE, Claghorn JL. Doxepin vs. chlordiazepoxide: A controlled comparison in neurotic outpatients. Curr Ther Res Clin Exp. 1968;10:514–519.
   Google Scholar
• Rickels K, Perloff M, Stepansky W, Dion HS, Case WG, Sapra RK. Doxepin and diazepam in general practice and hospital clinic neurotic patients: A collaborative controlled study. Psychophar-macologia. 1969;15:265–279.
   Google Scholar
• Verner JV, Jr. Comparison of imipramine and chlordiazepoxide in the treatment of the depressed and anxious patient. J Fla Med Assoc. 1969;56:15–21.
   Google Scholar
• Beaubien J, Ban TA, Lehman HE, Jarrold L. Doxepin in the treatment of psychoneurotic patients. Curr Ther Res Clin Exp. 1970;12:192–194.
   Google Scholar
• Derogatis LR, Covi L, Lipman RS, Rickels K. Dimensions of outpatient neurotic pathology: Comparison of a clinical versus an empirical assessment. J Consult Clin Psychol. 1970;34:164–171.
   Google Scholar
• Kay DW, Fahy T, Garside RF. A seven-month double-blind trial of amitriptyline and diazepam in ECT-treated depressed patients. Br J Psychiatry. 1970;117:667–671.
   Google Scholar
• Montgomery BA, Cullinan TR, Bayley AJ. A double-blind comparative trial of doxepin hydrochloride and chlordiazepoxide in anxiety and depression in general practice. Br J Clin Pract. 1970;24:207–209.
   Google Scholar
• Rickels K, Gordon PE, Jenkins BW, Perloff M, Sachs T, Stepan-sky W. Drug treatment in depressive illness. Dis Nerv Syst. 1970;31:30–42.
   Google Scholar
• Sterlin C, Ban TA, Lehmann HE, Jarrold L. A comparative evaluation of doxepin and chlordiazepoxide in the treatment of psychoneurotic outpatients. Curr Ther Res Clin Exp. 1970;12: 195–200.
   Google Scholar
• Butterworth AT, Watts RD. Treatment of hospitalized alcoholics with doxepin and diazepam. A controlled study. QJ Stud Alcohol. 1971;32:78–81.
   Google Scholar
• Claghorn J, Kellner R. When is a tranquillizer an antidepressant? Curr Ther Res Clin Exp. 1971;13:575–579.
   Google Scholar
• General Practitioner Clinical Trials: Antidepressant effects of tranquilizers. Practitioner. 1971;206:146–149
   Google Scholar
• Sim M, Bindman E, Conochie B, et al. The treatment of anxiety/ depressive states. Clin Trials J. 1971;8:22–27.
   Google Scholar
• Sterlin C, Ban TA, Jarrold L. The place of doxepin among the anxiolytic-sedative drugs. Curr Ther Res Clin Exp. 1972;14: 195–204.
   Google Scholar
• Goldstein BJ, Brauzer B, Steinbook RM, Jacobson AF. Psychotro-pic drug treatment of mixed anxiety and depression in nonpsychiat-ric office patients: Expected and unexpected findings?comparing doxepin, chlordiazepoxide and placebo. South Med J. 1973;66: 892–897.
   Google Scholar
• Johnson F, Sacco FA, Yellowley TW. Chlordiazepoxide and dothiepin compared in anxiety-depression in general practice. Practitioner. 1973;211:362–364.
   Google Scholar
• Overall JE, Brown D, Williams JD, Neill LT. Drug treatment of anxiety and depression in detoxified alcoholic patients. Arch Gen Psychiatry. 1973;29:218–225.
   Google Scholar
• Rickels K, Chung HR, Feldman HS, Gordon PE, Kelly EA, Weise CC. Amitriptyline, diazepam, and phenobarbital sodium in depressed outpatients. J Nerv Ment Dis. 1973;157:442–451.
   Google Scholar
• Covi L, Lipman RS, Derogatis LR, Smith JE, III, Pattison JH. Drugs and group psychotherapy in neurotic depression. Am J Psychiatry. 1974;131:191–198.
   Google Scholar
• d–Elia G, von Knorring L, Marcusson J, Mattsson B, Perris C, Persson G. A double blind comparison between doxepin and diaz-epam in the treatment of states of anxiety. Acta Psychiatr Scand Suppl. 1974;255: 35–46.
   Google Scholar
• Hare M. Treatment of anxiety and depression: A comparative trial of amitriptyline (Laroxyl) and diazepam (valium). Clin Trials J. 1974;11:39–44.
   Google Scholar
• Magnus RV. A placebo controlled trial of viloxazine with and without tranquillizers in depressive illness. J Int Med Res. 1975;3:207–213.
   Google Scholar
• Haskell DS, Gambill JD, Gardos G, McNair DM, Fisher S. Dox-epin or diazepam for anxious and anxious-depressed outpatients? J Clin Psychiatry. 1978;39:135–139.
   Google Scholar
• Russell GF, Niaz U, Wakeling A, Slade PD. Comparative double-blind trial of mianserin hydrochloride (Organon GB94) and diaz-epam in patients with depressive illness. Br J Clin Pharmacol. 1978;5\(Suppl 1):57S–65S.
   Google Scholar
• Remick RA, Fleming JA, Buchanan RA, Keller FD, Hamilton P, Loomer F, Miles JE. A comparison of the safety and efficacy of alprazolam and desipramine in moderately severe depression. Can J Psychiatry. 1985;30:597–601.
   Google Scholar
• Tiller J, Schweitzer I, Maguire K, Davies B. A sequential double-blind controlled study of moclobemide and diazepam in patients with atypical depression. J Affect Disord. 1989;16:181–187.
   Google Scholar
• Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand. 1990;81:185–189.
   Google Scholar
• Ansseau M, Devoitille JM, Papart P, Vanbrabant E, Mantanus H, Timsit-Berthier M. Comparison of adinazolam, amitriptyline, and diazepam in endogenous depressive inpatients exhibiting DST nonsuppression or abnormal contingent negative variation. J Clin Psychopharmacol. 1991;11:160–165.
   Google Scholar
• Lemoine P, Boulenger JP, Caillard V, Tanne N, Bonnet D. Compared efficacy of prazepam and clomipramine in major depression with anxiety: A multicenter controlled study. Pharmacopsychia-try. 1991;24:175–179.
   Google Scholar
• Rickels K, London J, Fox I, Hassman H, Csanalosi I, Weise C. Adinazolam, diazepam, imipramine, and placebo in major depressive disorder: A controlled study. Pharmacopsychiatry. 1991;24:127–131.
   Google Scholar
• Laakman G, Faltermaier-Temizel M, Bossert-Zaudig S, Baghai T, Lorkowski G. Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo. Psychophar-macology (Berl). 1995;120:109–115.
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
   Google Scholar
• PDR: Physicians' Desk Reference. Montvale, NJ: Thomson PDR, 2007.
   Google Scholar
• Smith WT, Londborg PD, Glaudin V, Painter JR. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: A double-blind study. Am J Psychiatry. 1998;155:1339–1345.
   Google Scholar
• Londborg PD, Smith WT, Glaudin V, Painter JR. Short-term cotherapy with clonazepam and fluoxetine: Anxiety, sleep disturbance, and core symptoms of depression. J Affect Disord. 2000;61:73–79.
   Google Scholar
• Smith WT, Londborg PD, Glaudin V, Painter JR. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? J Affect Disord. 2002;70:251–259.
   Google Scholar
• Fawcett J. Treating impulsivity and anxiety in the suicidal patient. Ann NY Acad Sci. 2001;932:94–102; discussion 102–105.
   Google Scholar
• Ferrari M, Barabas G, Matthews WS. Psychologic and behavioral disturbance among epileptic children treated with barbiturate anticonvulsants. Am J Psychiatry. 1983;140:112–113.
   Google Scholar
• Barabas G, Matthews WS. Barbiturate anticonvulsants as a cause of severe depression. Pediatrics. 1899;82:284–285.
   Google Scholar
• Brent DA, Crumrine PK, Varma RR, Allan M, Allman C. Phenoparbital treatment and major depressive disorder in children with epilepsy. Pediatrics. 1987;80:909–917.
   Google Scholar
• Rao AV. A controlled trial with –valium– in obsessive compulsive state. J Ind Med Assoc. 1964;42:564–567.
   Google Scholar
• Kraft IA, Ardali C, Duffy JH, Hart JT, Pearce P. A clinical study of chlordiazepoxide used in psychiatric disorders of children. Int J Neuropsych. 1965;1:433–437.
   Google Scholar
• Gundlach R, Engelhardt DM, Hankoff L, Paley H, Rudorfer L, Byrd E. A double-blind outpatient study of diazepam (valium) and placebo. Psychopharmacologia. 1966;9:81–92.
   Google Scholar
• McDowall A, Owen S, Robin AA. A controlled comparison of diazepam and amylobarbitone in anxiety states. Br J Psychiatry. 1966;112:629–631.
   Google Scholar
• Ryan HF, Merrill FB, Scott GE, Krebs R, Thompson BL. Increase in suicidal thoughts and tendencies. Association with diazepam therapy. JAMA. 1968;203:1137–1139.
   Google Scholar
• Hall RC, Joffe JR. Aberrant response to diazepam: A new syndrome. Am J Psychiatry. 1972;129:738–742.
   Google Scholar
• Lydiard RB, Laraia MT, Ballenger JC, Howell EF. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry. 1987;144:664–665.
   Google Scholar
• Cohen LS, Rosenbaum JF. Clonazepam: New uses and potential problems. J Clin Psychiatry. 1987;48(Suppl):50–56.
   Google Scholar
• Noyes R Jr, Duport RL, Pecknold JC, Rifkin A, Rubin RT, Swinson RP, Ballenger JC, Burrows GD. Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. Arch Gen Psychiatry. 1988;45:423–428.
   Google Scholar
• O–Sullivan GH, Noshirvani H, Basoglu M, Marks IM, Swinson R, Kuch K, Kirby M. Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder. Br J Psychiatry. 1994;165:79–86.
   Google Scholar
• Edwards JG, Inman WHW, Pearce GL, Rawson NSB. Prescription-event monitoring of 10,895 patients treated with alprazolam. Br J Psychiatry. 1991;158:387–392.
   Google Scholar
• PDR: Physicians' Desk Reference. Montvale, NJ: Medical Economics Company, 1997.
   Google Scholar
• Litchfield NB. Complications of intravenous diazepam?adverse psychological reactions. (An assessment of 16,000 cases.). Anesth Prog. 1980;28: 175–183.
   Google Scholar
• Short TG, Forrest P, Galletly DC. Paradoxical reactions to benzo-diazepines?a genetically determined phenomenon? Anaesth Intens Care. 1987;15:330–331.
   Google Scholar
• Lobo BL, Miwa LJ. Midazolam disinhibition reaction. Drug Intell Clin Pharm. 1988;22:725.
   PubMedGoogle Scholar
• Rodrigo CR. Flumazenil reverses paradoxical reaction with mida-zolam. Anesth Prog. 1991;38:65–68.
   Google Scholar
• Honan VJ. Paradoxical reaction to midazolam and control with flumazenil. Gastrointest Endosc. 1994;40:86–88.
   Google Scholar
• Thakker P, Gallagher TM. Flumazenil reverses paradoxical reaction to midazolam in a child. Anaesth Intens Care. 1996;24: 505–507.
   Google Scholar
• Thurston TA, Williams CG, Foshee SL. Reversal of a paradoxical reaction to midazolam with flumazenil. Anesth Analg. 1996;83:192.
   Google Scholar
• Khan LC, Lustik SJ. Treatment of a paradoxical reaction to mida-zolam with haloperidol. Anesth Analg. 1997;85:213–215.
   Google Scholar
• Massanari M, Novitsky J, Reinstein LJ. Paradoxical reactions in children associated with midazolam use during endoscopy. Clin Pediatr (Phila). 1997;36:681–684.
   Google Scholar
• Fulton SA, Mullen KD. Completion of upper endoscopic procedures despite paradoxical reaction to midazolam: A role for flu-mazenil? Am J Gastroenterol. 2000;95:809–811.
   Google Scholar
• Saltik IN, Ozen H. Role of flumazenil for paradoxical reaction to midazolam during endoscopic procedures in children. Am J Gas-troenterol. 2000;95:3011–3012.
   Google Scholar
• Weinbroum AA, Szold O, Ogorek D, Flaishon R. The mida-zolam-induced paradox phenomenon is reversible by flumazenil. Epidemiology, patient characteristics and review of the literature. Eur J Anaesthesiol. 2001;18:789–797.
   Google Scholar
• Robin C, Trieger N. Paradoxical reactions to benzodiazepines in intravenous sedation: A report of 2 cases and review of the literature. Anesth Prog. 2002;49:128–132.
   Google Scholar
• Sanders JC. Flumazenil reverses a paradoxical reaction to intravenous midazolam in a child with uneventful prior exposure to midazolam. Paediatr Anaesth. 2003;13:369–370.
   Google Scholar
• Graae F, Milner J, Rizzotto L, Klein RG. Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 1994;33:372–376.
   Google Scholar
• Salzman C, DiMascio A, Shader RI, Harmatz JS. Chlordiazep-oxide, expectation and hostility. Psychopharmacologia. 1969;14:38–45.
   Google Scholar
• Kochansky GE, Salzman C, Shader RI, Harmatz JS, Ogeltree AM. The differential effects of chlordiazepoxide and oxazepam on hostility in a small group setting. Am J Psychiatry. 1975;132: 861–863.
   Google Scholar
• Cherek DR, Spiga R, Roache JD, Cowan KA. Effects of triazolam on human aggressive, escape and point-maintained responding. Pharmacol Biochem Behav. 1991;40:835–839.
   Google Scholar
• Fillmore MT, Rush CR, Kelly TH, Hays L. Triazolam impairs inhibitory control of behavior in humans. Exp Clin Psychophar-macol. 2001;9:363–371.
   Google Scholar
• Dowd SM, Strong MJ, Janicak PG, Negrusz A. The behavioral and cognitive effects of two benzodiazepines associated with drug-facilitated sexual assault. J Forensic Sci. 2002;47:1101–1107.
   Google Scholar
• Edwards RA, Medlicott RW. Advantages and disadvantages of benzodiazepine prescription. NZ Med J. 1980;92:357–359.
   Google Scholar
• Roy-Byrne PP, Craske MG, Stein MB, Sullivan G, Bystritsky A, Katon W, Golinelli D, Sherbourne CD. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry. 2005;62:290–298.
   Google Scholar
• Hawkridge SM, Stein DJ. A risk-benefit assessment of pharmaco-therapy for anxiety disorders in children and adolescents. Drug Saf. 1998;19:283–297.
   Google Scholar
• Alexander AD. Evaluation of an ataractic (hydroxyzine) in 2025 patients as an adjunct in oral surgery. WV Dent J. 1960;34:56–59.
   Google Scholar
• Tornetta FJ. A comparison of droperidol, diazepam, and hydrox-yzine hydrochloride as premedication. Anesth Analg. 1977;56: 496–500.
   Google Scholar
• Herr GP, Conner JT, Schehl D, Dorey F. Comparison of IM diazepam and hydroxyzine as premedicants. Br J Anaes. 1982;54:3–9.
   Google Scholar
• Garber R. Management of tension and anxiety states with hydroxyzine hydrochloride. J Fla Med Assoc. 1958;45:549–552.
   Google Scholar
• Lipton MI. High dosages of hydroxyzine in out-patient treatment of severe neuroses and psychoses. Pa Med J. 1961;64:60–62.
   Google Scholar
• Shalowitz M. Evaluation of an ataraxic (hydroxyzine) in long-term therapy. Int Rec Med. 1961;174:357–361.
   Google Scholar
• Breslow L. Evaluation of hydroxyzine pamoate concentration as an ataractic. Curr Ther Res. 1968;10:421–427.
   Google Scholar
• Rickels K, Gordon PE, Zamostien BB, Case W, Hutchison J, Chung H. Hydroxyzine and chlordiazepoxide in anxious neurotic outpatients: A collaborative controlled study. Compr Psychiatry. 1970;11:457–474.
   Google Scholar
• Goldberg HL, Finnerty RJ. The use of hydroxyzine (Vistaril) in the treatment of anxiety neurosis. Psychosomatics. 1973;14: 38–41.
   Google Scholar
• Darcis T, Ferreri M, Natens J, Burtin B, Deram P. A multicentre double-blind placebo-controlled study investigating the anxi-olytic efficacy of hydroxyzine in patients with generalized anxiety. Hum Psychopharmacol. 1995;10:181–187.
   Google Scholar
• Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl). 1998;139: 402–406.
   Google Scholar
• Llorca PM, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, Faruch M, Macher JP, Sermet E, Servant D. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: A 3-month double-blind study. J Clin Psychiatry. 2002; 63:1020–1027.
   Google Scholar
• Roy-Byrne PP, Ward NG, Donnelly PJ. Valproate in anxiety and withdrawal syndromes. J Clin Psychiatry. 1989;50(Suppl): 44–48.
   Google Scholar
• Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry. 1990; 35:248–250.
   Google Scholar
• Lum M, Fontaine R, Elie R, Ontiveros A. Probable interaction of sodium divalproex with benzodiazepines. Prog Neuropsychop-harmacol Biol Psychiatry. 1991;15:269–273.
   Google Scholar
• Woodman CL, Noyes Jr R. Panic disorder: treatment with val-proate. J Clin Psychiatry. 1994;55:134–136.
   Google Scholar
• Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: A randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry. 2003;64:1245–1249.
   Google Scholar
• Crane D. Tiagabine for the treatment of anxiety. Depress Anxiety. 2003;18:51–52.
   Google Scholar
• Schwartz TL, Azhar N, Husain J, Nihalani N, Simionescu M, Coovert D, Jindal S, Tirmazi S. An open-label study of tiagabine as augmentation therapy for anxiety. Ann Clin Psychiatry. 2005;17:167–172.
   Google Scholar
• Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, Rickels K. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: Results of a placebo-controlled study. J Clin Psychiatry. 2005;66:1401–1408.
   Google Scholar
• Carpenter LL, Schecter JM, Tyrka AR, Mello AF, Mello MF, Haggarty R, Price LH. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J Clin Psychiatry. 2006;67:66–71.
   Google Scholar
• Chouinard G, Beauclair L, Belanger MC. Gabapentin: Long-term anti-anxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry. 1998;43: 305.
   Google Scholar
• Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000;20:467–471.
   Google Scholar
• Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, Liu-Dumaw M, Carter CM, Pande AC. A randomized, double-blind, placebo-controlled, fixed-dose, mul-ticenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23:240–249.
   Google Scholar
• Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD, Bielski RJ, Zimbroff DL, Davidson JR, Liu-Dumaw M. Pregabalin in generalized anxiety disorder: A placebo-controlled trial. Am J Psychiatry. 2003;160:533–540.
   Google Scholar
• Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC. Pre-gabalin for treatment of generalized anxiety disorder: A 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62:1022–1030.
   Google Scholar
• Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregaba-lin in the treatment of generalized anxiety disorder: Double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005;25:151–158.
   Google Scholar
• Frampton JE, Foster RH. Pregabalin: In the treatment of generalized anxiety disorder. CNS Drugs. 2006;20:685–693; discussion 694–695.
   Google Scholar
• Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: A 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and ven-lafaxine. J Clin Psychiatry. 2006;67: 771–782.
   Google Scholar
• Stein DJ. Pregabalin and venlafaxine improve symptoms of generalized anxiety disorder. Evid Based Ment Health. 2007;10:23.
   Google Scholar
• Adson DE, Kushner MG, Eiben KM, Schulz SC. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety. 2004;19:121–126.
   Google Scholar
• Kasper S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety. 2004;20:44–47.
   Google Scholar
• Hirschfeld RM, Weisler RH, Raines SR, Macfadden W. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: A secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67: 355–362.
   Google Scholar
• Galynker I, Khan A, Grebchenko Y, Ten A, Malaya L, Yanowitch P, Cohen LJ. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. J Clin Psychiatry. 2005;66:544.
   Google Scholar
• Tollefson GD, Sanger TM. Anxious-depressive symptoms in schizophrenia: A new treatment target for pharmacotherapy? Schizophr Res. 1999;35(Suppl):S13–21.
   Google Scholar
• Mintzer J, Faison W, Street JS, Sutton VK, Breier A. Olanzapine in the treatment of anxiety symptoms due to Alzheimer–s disease: A post hoc analysis. Int J Geriatr Psychiatry. 2001;16(Suppl 1): S71–77.
   Google Scholar
• Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60: 1079–1088.
   Google Scholar
• Littrell KH, Petty RG, Hilligoss NM, Kirshner CD, Johnson CG. The effect of olanzapine on anxiety among patients with schizophrenia: Preliminary findings. J Clin Psychopharmacol. 2003;23:523–525.
   Google Scholar
• Hollifield M, Thompson PM, Ruiz JE, Uhlenhuth EH. Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety. 2005;21:33–40.
   Google Scholar
• Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: A placebo controlled study. Biol Psychiatry. 2006;59:211–215.
   Google Scholar
• Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol. 1996;16:38–44.
   Google Scholar
• Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperi-done in generalized anxiety disorder: A double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66:1321–1325.
   Google Scholar
• Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006;67:381–385.
   Google Scholar
• Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol. 2005;25:497–499.
   Google Scholar
• Worthington JJ III, Kinrys G, Wygant LE, Pollack MH. Arip-iprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005;20:9–11.
   Google Scholar
• Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord. 2005;86:99–104.
   Google Scholar
• Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry. 1990;147:431–434.
   Google Scholar
• Davis LL, Kabel D, Patel D, Choate AD, Foslien-Nash C, Gurguis GN, Kramer GL, Petty F. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull. 1996;32: 647–652.
   Google Scholar
• Emsley RA, Buckley P, Jones AM, Greenwood MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol. 2003;17:210–215.
   Google Scholar
• Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004;65:217–221.
   Google Scholar
• Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2004;16: 189–194.
   Google Scholar
• Simon JS, Nemeroff CB. Aripiprazole augmentation of antide-pressants for the treatment of partially responding and nonre-sponding patients with major depressive disorder. J Clin Psychiatry. 2005;66:1216–1220.
   Google Scholar
• Vanelle JM, Douki S. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry. 2006;21:523–530.
   Google Scholar
• Mathews J, Garcia KS, Mintun MA, Sheline YI. Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: A pilot study. Psychiatry Res. 2006;146:149–155.
   Google Scholar
• Sagud M, Mihaljevic-Peles A, Muck-Seler D, Jakovljevic M, Pivac N. Quetiapine augmentation in treatment-resistant depression: A naturalistic study. Psychopharmacology (Berl). 2006;187: 511–514.
   Google Scholar
• Doree JP, Des Rosiers J, Lew V, Gendron A, Elie R, Stip E, Tourjman SV. Quetiapine augmentation of treatment-resistant depression: A comparison with lithium. Curr Med Res Opin. 2007;23:333–341.
   Google Scholar
• Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. Am J Psychiatry. 1995;152:183–190.
   Google Scholar
• Keck PE, Jr., Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry. 2000;61(Suppl 3):4–9.
   Google Scholar
• Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82–91.
   Google Scholar
• Barak Y, Mirecki I, Knobler HY, Natan Z, Aizenberg D. Suicid-ality and second generation antipsychotics in schizophrenia patients: A case-controlled retrospective study during a 5-year period. Psychopharmacology (Berl). 2004;175: 215–219.
   Google Scholar
• Ward A, Ishak K, Proskorovsky I, Caro J. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: A retrospective database study. Clin Ther. 2006;28:1912–1921.
   Google Scholar
• Dannon PN, Gon-Usishkin M, Gelbert A, Lowengrub K, Grunhaus L. Cognitive behavioral group therapy in panic disorder patients: The efficacy of CBGT versus drug treatment. Ann Clin Psychiatry. 2004;16:41–46.
   Google Scholar
• Azhar MZ: Comparison of fluvoxamine alone, fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan?implications for management by family doctors. Med J Malaysia. 2000;55:402–408.
   Google Scholar
• Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anasta-siades P, Gelder M. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry. 1994;164:759–769.
   Google Scholar
• Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P: A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59:441–448.
   Google Scholar
• Ost LG, Westling BE. Applied relaxation vs. cognitive behavior therapy in the treatment of panic disorder. Behav Res Ther. 1995;33:145–158.
   Google Scholar
• Ost LG, Westling BE, Hellstrom K. Applied relaxation, exposure in vivo and cognitive methods in the treatment of panic disorder with agoraphobia. Behav Res Ther. 1993;31:383–394.
   Google Scholar
• Taylor CB, Kenigsberg ML, Robinson JM. A controlled comparison of relaxation and diazepam in panic disorder. J Clin Psychiatry. 1982;43:423–425.
   Google Scholar
• Dhossche DM. Toxicology of suicide: Touchstone for suicide prevention? Med Sci Monit. 2003;9:SR9–SR19.
   Google Scholar
• Boyle D, Tobin JM. Pharmaceutical management of behavior disorders. J Med Soc NJ. 1961;58:427–429.
   Google Scholar
• Feldman PE. An analysis of the efficacy of diazepam. J Neurop-sych. 1962;5(Suppl 1):S62–67.
   Google Scholar
• Zucker HS. Strange behavior with oxazepam. NY State J Med. 1972;72:974.
   Google Scholar
• Lion JR, Azcarate CL, Koepke HH. –Paradoxical rage reactions– during psychotropic medication. Dis Nerv Syst. 1975;36:557–558.
   Google Scholar
• Goldney RD. Paradoxical reaction to a new minor tranquilizer. Med J Aust. 1977;1:139–140.
   Google Scholar
• Zisook S, DeVaul RA. Adverse behavioral effects of benzodiaz-epines. J Fam Pract. 1977;5:963–966.
   Google Scholar
• Gardos G. Disinhibition of behavior by antianxiety drugs. Psy-chosomatics. 1980;21:1025–1026.
   Google Scholar
• Rosenbaum JF, Woods SW, Groves JE, Klerman GL. Emergence of hostility during alprazolam treatment. Am J Psychiatry. 1984;141:792–793.
   Google Scholar
• Strahan A, Rosenthal J, Kaswan M, Winston A. Three case reports of acute paroxysmal excitement associated with alpra-zolam treatment. Am J Psychiatry. 1985;142:859–861.
   Google Scholar
• Binder RL. Three case reports of behavioral disinhibition with clonazepam. Gen Hosp Psychiatry. 1987;9:151–153.
   Google Scholar
• Kubacki A. Sexual disinhibition on clonazepam. Can J Psychiatry. 1987;32:643–645.
   Google Scholar
• Marrosu F, Marrosu G, Rachel MG, Biggio G. Paradoxical reactions elicited by diazepam in children with classic autism. Funct Neurol. 1987;2:355–361.
   Google Scholar
• Marchevsky S, Isaacs G, Nitzan I. Behavioral disinhibition with clonazepam. Gen Hosp Psychiatry. 1988;10:447.
   Google Scholar
• Fava M, Borofsky GF. Sexual disinhibition during treatment with a benzodiazepine: A case report. Int J Psychiatry Med. 1991;21:99–104.
   Google Scholar